Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986158 in advanced solid tumors
NL-OMON46213Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol in Nonhematologic neoplasms, small cell lung cancer (SCLC), triple-negative breast cancer (TNBC) and 3 more, sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Planned start Nov 2016; status: not yet recruiting.
02
Drugs
2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)triple-negative breast cancer (TNBC)ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON46213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46213.